MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Aandelen Lijst・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Gesloten

SectorGezondheidszorg

241.59 -0.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

236.04

Max

243.11

Belangrijke statistieken
By Trading Economics
Inkomsten	28M -33M
Verkoop	32M 245M
Winstmarge	-13.56
Werknemers	1,189
EBITDA	68M 15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+22.72% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.7B 15B
Vorige openingsprijs	241.63
Vorige sluitingsprijs	241.59

Nieuwssentiment

By Acuity

54%

46%

303 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

157.66 / 167.29 Steun & Weerstand

Ascendis Pharma A-S ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 apr 2026, 23:14 UTC

Winsten

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 apr 2026, 23:14 UTC

Winsten

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 apr 2026, 17:13 UTC

Belangrijke Marktbewegers

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 apr 2026, 23:39 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 apr 2026, 23:35 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 apr 2026, 22:41 UTC

Winsten

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 apr 2026, 22:38 UTC

Winsten

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 apr 2026, 22:15 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 apr 2026, 22:15 UTC

Marktinformatie

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 apr 2026, 22:14 UTC

Winsten

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 apr 2026, 22:12 UTC

Winsten

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 apr 2026, 22:11 UTC

Winsten

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 apr 2026, 22:11 UTC

Winsten

Lens Technology Swings to Loss in 1Q>300433.SZ

15 apr 2026, 22:07 UTC

Winsten

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 apr 2026, 21:34 UTC

Acquisities, Fusies, Overnames

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 apr 2026, 21:29 UTC

Populaire aandelen

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

15 apr 2026, 20:30 UTC

Winsten

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

15 apr 2026, 20:06 UTC

Marktinformatie

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 apr 2026, 19:46 UTC

Winsten

Acquisities, Fusies, Overnames

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 apr 2026, 19:25 UTC

Marktinformatie

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 apr 2026, 19:00 UTC

Marktinformatie

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 apr 2026, 18:58 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 apr 2026, 18:11 UTC

Acquisities, Fusies, Overnames

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 apr 2026, 17:45 UTC

Acquisities, Fusies, Overnames

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 apr 2026, 16:58 UTC

Winsten

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 apr 2026, 16:52 UTC

Winsten

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 apr 2026, 16:46 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 apr 2026, 16:37 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Ascendis Pharma A-S ADR Prognose

Koersdoel

By TipRanks

22.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 296.62 USD 22.72%

Hoogste 342 USD

Laagste 255 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ascendis Pharma A-S ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Gebaseerd op 13 analisten die aandelenratings hebben gegeven aan Ascendis Pharma A-S ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

157.66 / 167.29Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

303 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.